Terminology

EQS-News: CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Retrieved on: 
Friday, November 11, 2022
Patient safety, Forward-looking statement, EDGAR, Private Securities Litigation Reform Act, Gesellschaft mit beschränkter Haftung, Legislation, SEC, U.S. Securities and Exchange Commission, Terminology, Growth, CureVac, Instability, News, COVID-19, Risk management, Security (finance)

Examples include discussion of the potential efficacy of the companys vaccine and treatment candidates and the companys strategies, financing plans, growth opportunities and market growth.

Key Points: 
  • Examples include discussion of the potential efficacy of the companys vaccine and treatment candidates and the companys strategies, financing plans, growth opportunities and market growth.
  • Forward-looking statements are based on managements current beliefs and assumptions and on information currently available to the company.
  • However, these forward-looking statements are not a guarantee of the companys performance, and you should not place undue reliance on such statements.
  • Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.

EQS-News: tonies SE: tonies to launch cash capital increase targeting gross proceeds of up to EUR 60 million

Retrieved on: 
Friday, November 11, 2022
Forward-looking statement, Finance, Nature, Urban economics, Financial services, European, Council, Person, European Parliament, Securities Act of 1933, United Kingdom, Failure, II, European Economic Area, Achievement, Financial Services and Markets Act 2000, Terminology, SE, News, Acquisition, Directive 2014/65/EU, Relevance (Person of Interest), Security (finance), Medical device, EU

These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.

Key Points: 
  • These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.
  • These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described in this document.
  • Neither tonies SE nor any other person accepts any responsibility for the accuracy of the opinions expressed in this document or the underlying assumptions.
  • This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of tonies SE (forward-looking statements).

EQS-News: Energy Focus, Inc. Reports Third Quarter 2022 Financial Results

Retrieved on: 
Friday, November 11, 2022
Private Securities Litigation Reform Act, Light-emitting diode, Forward-looking statement, 100,000, Health, XXV, Nature, Terrorism, U.S. Securities and Exchange Commission, Workforce, LED, Pandemic, Q & A, Interim, Lighting, Webcast, Travel, Annual report, Nasdaq, Environment, Sale, Flood, Board, COVID-19, Fortune 500, NASDAQ, United States Navy, Energy, Solution, Safety, Public expenditure, Compliance, Time, EBITDA, Company, Government, Form 10-K, Maintenance, Earthquake, Terminology, Engineering, Fire, Growth, Security (finance), Instability, Industry, Public sector, Renewable energy, Video game, Aquaculture, Bank, Pharmaceutical industry, Director

Energy Focus, Inc. (NASDAQ:EFOI), a leader in sustainable, energy-efficient lighting and controls systems products for the commercial, military maritime and consumer markets, today announced financial results for its third quarter ended September 30, 2022.

Key Points: 
  • Energy Focus, Inc. (NASDAQ:EFOI), a leader in sustainable, energy-efficient lighting and controls systems products for the commercial, military maritime and consumer markets, today announced financial results for its third quarter ended September 30, 2022.
  • Loss from operations increased slightly as compared to a loss from operations of $2.2 million in the second quarter of 2022.
  • Unsecured promissory notes issued in September 2022, October 2022 and November 2022 resulted in net aggregate proceeds of $1.1 million.
  • Third Quarter 2022 Financial Results:
    Net sales were $1.8 million for the third quarter of 2022, compared to $2.7 million in the third quarter of 2021, a decrease of approximately $1.0 million, or 36%.

EQS-News: Polyvisions selects FRX Innovations’ Nofia® Technology for its line of FR PET Molded and Extruded Products

Retrieved on: 
Friday, November 11, 2022
Benchmark, EV, FR, PCR, GreenScreen for Safer Chemicals, UL, Electronics, Polymer, Medicine, Solution, Company, Plastic, Engineering, Hospital, CTI, EPA, News, TSX Venture Exchange, Environment, Global, TSX, Chroma key, Phrase, PET, Port of Antwerp, Legislation, Efficiency, Ernst & Young Entrepreneur of the Year Award, FSE, HDT, Port, Terminology, Flanders, Consumer, Textile, OTC, Membrane, Goal, Safety, FRX, Flanders Investment and Trade, TCO, 3D printing, Thermoplastic, Printed circuit board, PolyVision (company)

Nofias unique polymeric phosphorus-based chemistry helps make DuraPET more sustainable and technically superior for polyester medical and consumer electronics applications.

Key Points: 
  • Nofias unique polymeric phosphorus-based chemistry helps make DuraPET more sustainable and technically superior for polyester medical and consumer electronics applications.
  • Nofia Homopolymers and Copolymer Flame retardant additives have achieved the highest rating of Benchmark 3 in the well-recognized Green Screen Assessment.
  • We looked at a lot of non-halogenated FR additives, says Rick Wilson of PolyVisions, but none performed as well as Nofia Polyphosphonates in mechanicals and FR performance.
  • DuraPET 624 FR is a graft modified PET material that has a UL V0 listing for flame retardancy enabled by Nofia non-halogenated flame retardant additives.

DoubleVerify Announces Pricing of Secondary Offering by Selling Stockholders

Retrieved on: 
Friday, November 11, 2022
Professional Services, Data Management, Security, Data Analytics, Technology, Software, Networks, Ecosystem, Forward-looking statement, Investment, NYSE, Telephone, Sale, Prospectus, Goldman Sachs, U.S. Securities and Exchange Commission, DV, Terminology, Security (finance)

The offering is expected to close on November 15, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on November 15, 2022, subject to the satisfaction of customary closing conditions.
  • DoubleVerify will not receive any proceeds from the sale of shares in the offering.
  • The offering of common stock is being made only by means of a prospectus supplement and accompanying prospectus.
  • This press release includes forward-looking statements, including with respect to the proposed secondary offering.

Euro Manganese Commences Demonstration Plant Commissioning

Retrieved on: 
Thursday, November 10, 2022
Forward-looking statement, Demonstration, Demonstration plant, Risk, Pandemic, News, Coronavirus, Project, Company, Terminology, Manganese, Growth, Industry, SEDAR, COVID-19, Risk management, EV

Certain statements in this news release constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws.

Key Points: 
  • Certain statements in this news release constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws.
  • Such forward-looking information or statements include, but are not limited to, statements regarding the: Companys plans regarding the commissioning of the Demonstration Plant, the timeframe for delivery of samples to interested parties, expected requests for Demonstration Plant samples, and the desirability and demand for the Companys products.
  • Readers are cautioned not to place undue reliance on forward-looking information or statements.
  • These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement.

Dave Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Forecasting, ATM, Marketing, Method, Investment, Workforce, U.S. Securities and Exchange Commission, Advertising, Monthly, Private Securities Litigation Reform Act, Depreciation, Mission statement, SEC, EBITDA, Government, Company, Adjustment, Terminology, GAAP, Growth, Australian Transaction Reports and Analysis Centre, Security (finance), Member, Industry, COVID-19, Income, Risk management, Medical device, Bank

LOS ANGELES, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dave Inc. (Nasdaq: DAVE, DAVEW) (“Dave” or the “Company”), one of the leading U.S. neobanks on a mission to build products that level the financial playing field, today reported its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • We are reiterating our guidance based on our 3Q22 performance and the continued positive trends that were seeing in the business, said Kyle Beilman, Chief Financial Officer of Dave.
  • The Company is reiterating its guidance for fiscal year 2022:
    Dave will host a conference call and webcast to discuss third quarter 2022 financial results and business operations updates today, Thursday, November 10, 2022, at5:30 pm ET.
  • Hosting the call will beJason Wilk, Co-Founder and Chief Executive Officer, andKyle Beilman, Chief Financial Officer.
  • Dave is on a mission to build products that level the financial playing field.

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 10, 2022
NYSE American, HCT, Research, Sale, Public relations, CGMP, Company, GMP, Degenerative disease, Form 8-K, Review, IV, Marketing, NYSE, IAP, Telephone, Incidence, VCN, SEC, Time, Cancer, Orphan drug, Patient, Neck, Acquisition, Private Securities Litigation Reform Act, PDAC, SIOP, Brain, Neoplasm, VRE, DSMC, AEMPS, Clinical trial, Maintenance, Terminology, Growth, Retinoblastoma, Congress, FDA, Trial of the century, Income, GLOBE, University, Head, ESMO, International Society, Durvalumab, Data, Safety, Hospital Sant Joan de Déu Barcelona, Therapy, Insurance, Vancomycin, Mobile phone, Pharmaceutical industry, American

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the quarter ended September 30, 2022, and provided a corporate update.
  • We are encouraged by our clinical results demonstrating the therapeutic potential of Therivas oncology-focused platform, said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • In October 2022, the Company rebranded as Theriva Biologics and began trading on NYSE American under the new ticker symbol TOVX.
  • ET to review the third quarter 2022 operational highlights and financial results.

Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, CELU, ATM, IND, Acute leukemia, Abstract, U.S. Securities and Exchange Commission, Food, Risk, Communication, EST, Research, Biology, Annual report, GBM, Private Securities Litigation Reform Act, Technology, Sale, HER2, Executive Committee, YA, COVID-19, Securities Act of 1933, Regulation of tobacco by the U.S. Food and Drug Administration, CAR, SEC, Chimeric antigen receptor T cell, Securities Exchange Act of 1934, SITC, Senior, Cancer, Form 10-K, General manager, AML, Clinical trial, Terminology, NK, Patient, Treatment, MRD, Security (finance), Drug Quality and Security Act, Lymphoid leukemia, Degenerative disease, Insurance, Industry, FDA, Income, Pharmaceutical industry, Vaccine, Music, Reinsurance, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September30, 2022, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September30, 2022, and provided a corporate update.
  • Celularity submitted an investigational new drug application (IND) for CYCART-19 in the first quarter of 2022, and in May 2022, the FDA requested additional information before Celularity can proceed with the planned first-in-human Phase 1/2 clinical trial of CYCART-19.
  • In September 2022, Celularity received cash proceeds net of discount of approximately $39.2 million as a pre-paid advance from Yorkville.
  • If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
CELU, Dove Medical Press, Marketing, TCR, U.S. Securities and Exchange Commission, Instituto de Biologia Molecular e Celular, Risk, Cytokine release syndrome, De novo, Neoplasm, Communication, Biology, Annual report, Private Securities Litigation Reform Act, Sale, Imugene, CAR, Cancer, CRS, SEC, PMID, CRISPR, Form 10-K, Clinical trial, Terminology, NK, Patient, Immune system, PBMC, Security (finance), Industry, Synergy, CD19, Vaccine

One of the fields unanswered questions is whether treatment-nave allogeneic CAR T cells are superior to cancer patient-derived T cells for product manufacturing to improve overall responses against solid tumors.

Key Points: 
  • One of the fields unanswered questions is whether treatment-nave allogeneic CAR T cells are superior to cancer patient-derived T cells for product manufacturing to improve overall responses against solid tumors.
  • This combination strategy was evaluated using two allogeneic CAR T cell products generated from peripheral blood mononuclear cells (PBMC) and placental T cells, respectively.
  • CYCART-19 T cells induced potent cytolytic activity against solid tumor cells infected with onCARlytics.
  • Interestingly, while we observed comparable anti-tumor activity between PBMC-derived CD19-CAR T cells and CYCART-19, differences in cytokine secretion were detected.